Carcinoid Tumor 

  • Author: Cameron K Tebbi, MD; Chief Editor: Max J Coppes, MD, PhD, MBA   more...
 
Updated: Dec 20, 2011
 

Background

Origin and general involvement and presentation

Carcinoid tumors are derived from primitive stem cells in the gut wall but can be seen in other organs,[1] including the lungs,[2] mediastinum, thymus,[3] liver, pancreas, bronchus, ovaries,[4] prostate,[5] and kidneys.[6] In children, most tumors occur in the appendix and are benign and asymptomatic.

Most carcinoid tumors are slow growing and indolent without symptoms. Nevertheless, aggressive and metastatic disease (eg, to the brain) does occur. Even tumors in the appendix can metastasize.[7, 8] Depending on the size and location, carcinoid tumors can cause various symptoms, including carcinoid syndrome. Carcinoid tumors of the ileum and jejunum, especially those larger than 1 cm, are most prone to produce this syndrome, at least in adults.

Classification

Carcinoid tumors generally are classified based on the location in the primitive gut (ie, foregut, midgut, hindgut) that gives rise to the tumor.

Foregut carcinoid tumors are divided into sporadic primary tumors and tumors secondary to achlorhydria. The term sporadic primary foregut tumor encompasses carcinoids of the lung, bronchus, stomach, proximal duodenum, and pancreas.

Midgut tumors are derived from the second portion of the duodenum, the jejunum, the ileum, and the right colon. The image below shows the distribution of carcinoid tumors.

Distribution of carcinoid tumors. Distribution of carcinoid tumors.

These account for 60-80% of all carcinoid tumors (especially those of the appendix and distal ileum) in adults and are also seen in children.[9] Appendicular carcinoid tumors are most common.[10, 11] In children, more than 70% of these tumors occur at the tip of the appendix and are often an incidental finding in appendectomy specimens. In one study, carcinoid tumors were found in 0.169% of 4747 appendectomies.[12] Bulky tumors are relatively rare and require somewhat extensive cecectomy or, when tumor infiltration is beyond the cecum, ileocecal resection.[13, 14, 11]

Hindgut carcinoid tumors include those of the transverse colon, descending colon, and rectum.

Carcinoid tumors can also arise from the Meckel diverticulum, cystic duplications, and the mesentery. Each of these entities has distinctive clinical, histochemical, and secretory features. For example, foregut carcinoids are argentaffin negative and have low serotonin content but secrete 5-hydroxytryptophan (5-HTP), histamine, and several polypeptide hormones. These tumors can metastasize to bone and may be associated with atypical carcinoid syndrome, acromegaly, Cushing disease, other endocrine disorders, telangiectasia, or hypertrophy of the skin in the face and upper neck.

Midgut carcinoids are argentaffin positive and can produce high levels of serotonin 5-hydroxytryptamine (5-HT), kinins, prostaglandins, substance P (SP), and other vasoactive peptides. These tumors have a rare potential to produce corticotropic hormone (previously adrenocorticotropic hormone [ACTH]). Bone metastasis is uncommon.

Hindgut carcinoids are argentaffin negative and rarely secrete 5-HT, 5-HTP, or any other vasoactive peptides. Therefore, they do not produce related symptomatology. Bone metastases are not uncommon in these tumors.

Next

Pathophysiology

Carcinoid tumors are of neuroendocrine origin and derived from primitive stem cells, which can give rise to multiple cell lineages. In the intestinal tract, these tumors develop deep in the mucosa, growing slowly and extending into the underlying submucosa and mucosal surface. This results in the formation of small firm nodules, which bulge into the intestinal lumen. These tumors have a yellow, tan, or gray-brown appearance that can be observed through the intact mucosa. The yellow color is a result of cholesterol and lipid accumulation within the tumor. Tumors can have a polypoid appearance and occasionally become ulcerated. With expansion and infiltration through the submucosa into the muscularis propria and serosa, carcinoid tumors can involve the mesentery. Metastases to the mesenteric lymph node and liver, ovaries, peritoneum, and spleen can occur.

Upon histologic examination, carcinoid tumors have 5 distinctive patterns: (1) solid, nodular, and insular cords; (2) trabecular or ribbons with anastomosing features; (3) tubules and glands or rosettelike patterns; (4) poorly differentiated or atypical patterns; and (5) mixed patterns. A combination of these patterns is often observed. Tubules can contain mucinous secretions, and individual tumor cells can contain mucin-positive material, which includes the various acidic and neutral intestinal mucin. Tumors rarely have eosinophilic stroma. Capillaries are often prominent. Cells are uniformly round or polygonal with a central nucleus and punctate chromatin as well as small nucleoli and infrequent mitosis. The cytoplasm can be slightly acidophilic, basophilic, or amphophilic. Eosinophilic granules may be present. Immunohistochemically, these tumors have a strong positive reaction to keratin and neuroendocrine markers. These include chromogranin and synaptophysin.

In midgut carcinoids, cells are arranged in closely packed, round, regular, monomorphous masses. In the appendix, carcinoids appear as discrete yellow nodules in the lumen. Lesions associated with diffuse wall thickening are relatively uncommon. Carcinoid tumors commonly affect the tip of the appendix. Most carcinoid tumors invade the wall of the appendix, and lymphatic involvement is nearly universal. About 75% of patients have evidence of peritoneal involvement. However, only a few patients have regional or distant dissemination. The size of the tumor can be correlated with outcome of the disease; tumors smaller than 1.5 cm in diameter (after formalin fixation) rarely result in distant metastases or recurrences.

Carcinoid tumors can be associated with concentric and elastic vascular sclerosis that results in obliteration of vascular lumina and ischemia. A common finding is elastosis and fibrosis that surround nests of the tumor cells and that result in matting of the involved tissues and lymph nodes. Fibroblastic proliferation may result from the stimulation of fibroblast cells by growth factor. This stimulation may be a result of a local release of tumor growth factor (TGF)-beta, beta–fibroblast growth factor (beta-FGF), and platelet-derived growth factor.

Other products of carcinoid tumors include the following:

  • Acid phosphatase
  • Alpha-1-antitrypsin
  • Amylin
  • Atrial natriuretic polypeptide
  • Calbindin-D28k
  • Catecholamines
  • Dopamine
  • Fibroblast growth factor
  • Gastrin
  • Gastrin-releasing peptide (bombesin)
  • Glucagon, glicentin
  • 5-Hydroxyindoleacetic acid (5-HIAA)
  • 5-Hydroxytryptamine (5-HT)
  • Histamine
  • Insulin
  • Kallikrein
  • Kinins
  • Motilin
  • Neuropeptide
  • Neurotensin
  • Pancreastatin
  • Pancreatic polypeptide
  • Platelet-dermal growth factor
  • Prostaglandins
  • Pyroglutamyl-glutamyl-prolinamide
  • Secretin
  • Serotonin
  • Somatostatin (ie, SRIF)
  • Tachykinins
  • Neuropeptide K
  • Neuropeptide A
  • Substance P (SP)
  • Transforming growth factor-beta
  • Vasoactive intestinal polypeptide (VIP)

Classic carcinoid tumor cells are argentaffinic and argyrophilic. At present, immunostain and hormonal markers are used for diagnosis. Carcinoid tumors of mediastinum can be misclassified as thymoma.

Carcinoids may have somatostatin receptors. Five identified somatostatin receptors are members of the G-protein receptor family. Five distinct genes on chromosomes 11, 14, 16, 17, and 20 encode somatostatin receptors. Somatostatin receptors are used to advantage for diagnosing and treating this disease.

Carcinoid tumors have high potential for metastasis. These cells produce a significant amount of beta-catenin, which enables the tumor cell adhesion, thus promoting metastasis. Induction of Raf1 results in decreased adhesion of carcinoid cells and may be important in the metastatic process.[15]

Previous
Next

Epidemiology

Frequency

United States

Carcinoids are the most common neuroendocrine tumors, with an estimated 1.5 clinical cases per 100,000 population. The incidence in autopsy cases is higher than this at 650 cases per 100,000 population. Evidence in adults suggests that overall incidence of carcinoid tumors has been steadily increasing.[16] The exact incidence in children is not known. Most tumors occur in adults and are rare in children.

International

In 1980-1989, the overall age-standardized incidence rate for male and female populations in England were estimated to be 0.71 (0.68-0.75 and 0.87 (0.83-0.91), respectively. In Scotland, the respective rates were 1.17 (0.91-1.44) per 100,000 population and 1.36 (1.09-1.63) per 100,000 population.[17]

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Cameron K Tebbi, MD  Professor of Pediatrics, Chief, Division of Pediatric Hematology-Oncology, University of South Florida College of Medicine; Director, Children's Medical Services, Pediatric Hematology/Oncology, Tampa Division, State of Florida Department of Health

Cameron K Tebbi, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, Histiocyte Society, and International Society of Paediatric Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Kathleen M Sakamoto, MD, PhD  Professor and Chief, Division of Hematology-Oncology, Vice-Chair of Research, Mattel Children's Hospital at UCLA; Co-Associate Program Director of the Signal Transduction Program Area, Jonsson Comprehensive Cancer Center, California Nanosystems Institute and Molecular Biology Institute, University of California, Los Angeles, David Geffen School of Medicine

Kathleen M Sakamoto, MD, PhD is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society for Experimental Hematology, Society for Pediatric Research, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Timothy P Cripe, MD, PhD  Professor of Pediatrics, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center; Clinical Director, Musculoskeletal Tumor Program, Co-Medical Director, Office for Clinical and Translational Research, Cincinnati Children's Hospital Medical Center; Director of Pilot and Collaborative Clinical and Translational Studies Core, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine

Timothy P Cripe, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Samuel Gross, MD  Professor Emeritus, Department of Pediatrics, University of Florida; Clinical Professor, Department of Pediatrics, University of North Carolina; Adjunct Professor, Department of Pediatrics, Duke University

Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA  Senior Vice President, Center for Cancer and Blood Disorders, Children's National Medical Center; Professor of Medicine, Oncology, and Pediatrics, Georgetown University School of Medicine; Clinical Professor of Pediatrics, George Washington University School of Medicine and Health Sciences

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Broaddus RR, Herzog CE, Hicks MJ. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med. Sep 2003;127(9):1200-3. [Medline].

  2. Moraes TJ, Langer JC, Forte V, et al. Pediatric pulmonary carcinoid: a case report and review of the literature. Pediatr Pulmonol. Apr 2003;35(4):318-22. [Medline].

  3. Soga J, Yakuwa Y, Osaka M. Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. Oct 1999;5(5):285-92. [Medline].

  4. Piura B, Dgani R, Zalel Y, et al. Malignant germ cell tumors of the ovary: a study of 20 cases. J Surg Oncol. Jul 1995;59(3):155-61. [Medline].

  5. Murali R, Kneale K, Lalak N, Delprado W. Carcinoid tumors of the urinary tract and prostate. Arch Pathol Lab Med. Nov 2006;130(11):1693-706. [Medline].

  6. Romero FR, Rais-Bahrami S, Permpongkosol S, Fine SW, Kohanim S, Jarrett TW. Primary carcinoid tumors of the kidney. J Urol. Dec 2006;176(6 Pt 1):2359-66. [Medline].

  7. Hlatky R, Suki D, Sawaya R. Carcinoid metastasis to the brain. Cancer. Dec 1 2004;101(11):2605-13. [Medline].

  8. Volpe A, Willert J, Ihnken K, et al. Metastatic appendiceal carcinoid tumor in a child. Med Pediatr Oncol. Mar 2000;34(3):218-20. [Medline].

  9. Schmittenbecher PP. Carcinoid tumours of the appendix in children--epidemiology, clinical aspects and procedures. Eur J Pediatr Surg. Dec 2001;11(6):428. [Medline].

  10. Bethel CA, Bhattacharyya N, Hutchinson C, et al. Alimentary tract malignancies in children. J Pediatr Surg. Jul 1997;32(7):1004-8; discussion 1008-9. [Medline].

  11. Pelizzo G, La Riccia A, Bouvier R, et al. Carcinoid tumors of the appendix in children. Pediatr Surg Int. Jul 2001;17(5-6):399-402. [Medline].

  12. Doede T, Foss HD, Waldschmidt J. Carcinoid tumors of the appendix in children--epidemiology, clinical aspects and procedure. Eur J Pediatr Surg. Dec 2000;10(6):372-7. [Medline].

  13. Soreide JA, van Heerden JA, Thompson GB, et al. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg. Nov 2000;24(11):1431-6. [Medline].

  14. D'Aleo C, Lazzareschi I, Ruggiero A, Riccardi R. Carcinoid tumors of the appendix in children: two case reports and review of the literature. Pediatr Hematol Oncol. Jul-Aug 2001;18(5):347-51. [Medline].

  15. Greenblatt DY, Kunnimalaiyaan M, Chen H. Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion. Am J Surg. Mar 2007;193(3):331-5; discussion 335. [Medline].

  16. Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician. Aug 1 2006;74(3):429-34. [Medline].

  17. Newton JN, Swerdlow AJ, dos Santos Silva IM, et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer. Nov 1994;70(5):939-42. [Medline].

  18. Lal DR, Clark I, Shalkow J, et al. Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer. Oct 15 2005;45(5):683-6. [Medline].

  19. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. Jun 2001;119(6):1647-51. [Medline].

  20. Fauroux B, Aynie V, Larroquet M, et al. Carcinoid and mucoepidermoid bronchial tumours in children. Eur J Pediatr. Dec 2005;164(12):748-52. [Medline].

  21. Wang WP, Guo C, Berney DM, et al. Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol. Apr 2010;34(4):519-24. [Medline].

  22. Uskul BT, Turker H, Dincer IS, Melikoglu A, Tasolar O, Tahaoglu C. A primary tracheal carcinoid tumor masquerading as chronic obstructive pulmonary disease. South Med J. May 2008;101(5):546-9. [Medline].

  23. Atoui R, Almarzooqi S, Saleh W, Marcovitz S, Mulder D. Bronchopulmonary carcinoid tumor associated with Cushing syndrome. Ann Thorac Surg. Nov 2008;86(5):1688-90. [Medline].

  24. Capovilla M, Kambouchner M, Bernier M, Soulier A, Tissier F, Saintigny P. Late cerebellar relapse of a juvenile bronchial carcinoid. Clin Lung Cancer. Mar 2007;8(5):339-41. [Medline].

  25. Igaz P. MEN1 clinical background. Adv Exp Med Biol. 2009;668:1-15. [Medline].

  26. Lin ZM, Chang YL, Lee CY, Wang CP, Hsiao TY. Simultaneous typical carcinoid tumour of larynx and occult papillary thyroid carcinoma. J Laryngol Otol. Jan 2008;122(1):93-6. [Medline].

  27. Aubry MC, Thomas CF Jr, Jett JR, Swensen SJ, Myers JL. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest. Jun 2007;131(6):1635-43. [Medline].

  28. Petrou A, Papalambros A, Papaconstantinou I, et al. Gastric carcinoid tumor in association with hepatocellular carcinoma: a case report. South Med J. Nov 2008;101(11):1170-2. [Medline].

  29. [Guideline] Dreijerink KM, Roijers JF, van der Luijt RB, et al. [Multiple endocrine neoplasia type 1: recent developments and guidelines for DNA diagnosis and periodic clinical monitoring]. Ned Tijdschr Geneeskd. Dec 16 2000;144(51):2445-9. [Medline].

  30. Yazawa K, Kuroda T, Watanabe H, et al. Multiple carcinoids of the duodenum accompanied by type I familial multiple endocrine neoplasia. Surg Today. 1998;28(6):636-9. [Medline].

  31. Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer. Nov 1 2001;94(3):444-8. [Medline].

  32. Vageli D, Danill Z, Dahabreh J. Microsatellite instability and loss of heterozygosity at the MEN1 locus in lung carcinoid tumors: a novel approach using real-time PCR with melting curve analysis in histopathologic material. Oncol Rep. 2006;15:557-64.

  33. D'Adda T, Pizzi S, Azzoni C. Different patterns of 11q allelic losses in digestive endocrine tumors. Hum Pathol. 2002;33:322-9.

  34. Pizzi S, D'Adda T, Azzoni c. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol. 2002;196:401-7.

  35. Pizzi S, D'Adda T, Azzoni C, et al. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol. Apr 2002;196(4):401-7. [Medline].

  36. Jakobovitz O, Nass D, DeMarco L. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab. 1996;81:3164-7.

  37. Jakobovitz O, Nass D, DeMarco L, et al. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab. Sep 1996;81(9):3164-7. [Medline].

  38. Yamaguchi M, Hirose K, Hirai N. HER2 expression in gastrointestinal carcinoid tumors: high in intestinal but not in gastric tumors. Surg Today. 2007;37(3):270-1. [Medline].

  39. Fujiki K, Duerr EM, Kikuchi H, et al. Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology. Sep 2008;135(3):907-16, 916.e1-2. [Medline].

  40. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. Oct 1987;5(10):1502-22. [Medline].

  41. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. Nov 1983;1(11):727-40. [Medline].

  42. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. Dec 31 1987;317(27):1699-701. [Medline].

  43. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg. Feb 1994;178(2):187-211. [Medline].

  44. Mani S, Modlin IM, Ballantyne G, et al. Carcinoids of the rectum. J Am Coll Surg. Aug 1994;179(2):231-48. [Medline].

  45. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. Mar 18 1999;340(11):858-68. [Medline].

  46. Carling RS, Degg TJ, Allen KR, et al. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem. Nov 2002;39(Pt 6):577-82. [Medline].

  47. Saqi A, Alexis D, Remotti F, Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol. Mar 2005;123(3):394-404. [Medline].

  48. Monsieurs MA, Thierens HM, Vral A, et al. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun. Apr 2001;22(4):367-74. [Medline].

  49. Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM. Apr 1998;91(4):295-301. [Medline].

  50. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. Feb 2001;86(2):895-902. [Medline].

  51. Dubois S, Morel O, Rodien P, et al. A Pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-Fluoro-[18F]L-dihydroxyphenylalanine positron emission/computed tomography imaging in a patient with Cushing's syndrome. J Clin Endocrinol Metab. Dec 2007;92(12):4512-3. [Medline].

  52. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. Mar 2007;11(3):264-71. [Medline].

  53. Lefebvre S, De Paepe L, Abs R, et al. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion. Eur J Endocrinol. Sep 1995;133(3):320-4. [Medline].

  54. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. Feb 1999;17(2):600-6. [Medline].

  55. Corleto VD, Angeletti S, Schillaci O, et al. Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol. Apr 2000;11(4):491-3. [Medline].

  56. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. Dec 10 2011;378(9808):2005-12. [Medline].

  57. Alvarez MC, Macias AA, Saurez MG, Fernandez ML, Lage DA. Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells. Cancer Biol Ther. Jun 2007;6(6):853-5. [Medline].

  58. Kwaan MR, Goldberg JE, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Arch Surg. May 2008;143(5):471-5. [Medline].

  59. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. Dec 2006;140(6):891-7; discussion 897-8. [Medline].

  60. Bertoletti L, Elleuch R, Kaczmarek D, Jean-Francois R, Vergnon JM. Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor. Chest. Nov 2006;130(5):1405-11. [Medline].

  61. Fornaro R, Frascio M, Sticchi C, et al. Appendectomy or right hemicolectomy in the treatment of appendiceal carcinoid tumors?. Tumori. Nov-Dec 2007;93(6):587-90. [Medline].

  62. Bamboat ZM, Berger DL. Is right hemicolectomy for 2.0-cm appendiceal carcinoids justified?. Arch Surg. Apr 2006;141(4):349-52; discussion 352. [Medline].

  63. Spunt SL, Pratt CB, Rao BN, et al. Childhood carcinoid tumors: the St Jude Children's Research Hospital experience. J Pediatr Surg. Sep 2000;35(9):1282-6. [Medline].

  64. Landry CS, Woodall C, Scoggins CR, McMasters KM, Martin RC 2nd. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg. Jul 2008;143(7):664-70; discussion 670. [Medline].

  65. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. Nov 2006;55(11):1586-91. [Medline].

  66. Anderson JR, Wilson BG. Carcinoid tumours of the appendix. Br J Surg. Jul 1985;72(7):545-6. [Medline].

  67. Andersson A, Bergdahl L. Carcinoid tumors of the appendix in children. A report of 25 cases. Acta Chir Scand. 1977;143(3):173-5. [Medline].

  68. Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion. 1994;55 Suppl 3:107-13. [Medline].

  69. Carrasco CH, Charnsangavej C, Ajani J, et al. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. Jul 1986;147(1):149-54. [Medline].

  70. Carretta A, Chiesa G, Magnani P, et al. Imaging of bronchial carcinoid tumors associated to Cushing syndrome with 111In-Octreoscan scintigraphy and immunoscintigraphy with anti-chromogranin monoclonal antibodies. Report of two cases. J Cardiovasc Surg (Torino). Apr 1997;38(2):191-4. [Medline].

  71. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 1993;32(2):107-14. [Medline].

  72. Chejfec G, Capella C, Solcia E, et al. Amphicrine cells, dysplasias, and neoplasias. Cancer. Dec 1 1985;56(11):2683-90. [Medline].

  73. Chow CW, Sane S, Campbell PE, Carter RF. Malignant carcinoid tumors in children. Cancer. Feb 15 1982;49(4):802-11. [Medline].

  74. Cohen T, Gluzman-Poltorak Z, Brodzky A, et al. Neuroendocrine cells along the digestive tract express neuropilin-2. Biochem Biophys Res Commun. Jun 8 2001;284(2):395-403. [Medline].

  75. Corpron CA, Black CT, Herzog CE, et al. A half century of experience with carcinoid tumors in children. Am J Surg. Dec 1995;170(6):606-8. [Medline].

  76. Craig SR, Hamzah M, Walker WS. Video-assisted thoracoscopic pneumonectomy for bronchial carcinoid tumor in a 14-year-old girl. J Pediatr Surg. Dec 1996;31(12):1724-6. [Medline].

  77. de Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. Apr 1997;24(4):368-71. [Medline].

  78. Diaco DS, Hajarizadeh H, Mueller CR, et al. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg. May 1995;169(5):523-8. [Medline].

  79. Feldman JM. Carcinoid tumors and syndrome. Semin Oncol. Sep 1987;14(3):237-46. [Medline].

  80. Gartner LA, Voorhess ML. Adrenocorticotropic hormone--producing thymic carcinoid in a teenager. Cancer. Jan 1 1993;71(1):106-11. [Medline].

  81. Hajarizadeh H, Ivancev K, Mueller CR, et al. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg. May 1992;163(5):479-83. [Medline].

  82. Han HS, Kim HS, Woo DK, et al. Loss of heterozygosity in gastric neuroendocrine tumor. Anticancer Res. Sep-Oct 2000;20(5A):2849-54. [Medline].

  83. Hause DW, Harvey JC. Endobronchial carcinoid and mucoepidermoid carcinoma in children. J Surg Oncol. Apr 1991;46(4):270-2. [Medline].

  84. Hulka GF, Rothschild MA, Warner BW, Bove KE. Carcinoid tumor of the trachea in a pediatric patient. Otolaryngol Head Neck Surg. Jun 1996;114(6):822-5. [Medline].

  85. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. Aug 2005;90(8):4955-62. [Medline].

  86. Johnson LA, Lavin P, Moertel CG, et al. Carcinoids: the association of histologic growth pattern and survival. Cancer. Mar 1 1983;51(5):882-9. [Medline].

  87. Kamiyoshihara M, Hirai T, Kawashima O, et al. Low-grade malignant tumors of the lung: is lymph node dissection necessary?. Oncol Rep. Jul-Aug 1998;5(4):841-3. [Medline].

  88. Kema IP, Willemse PH, De Vries EG. Carcinoid tumors. N Engl J Med. Aug 5 1999;341(6):453-4; discussion 454-5. [Medline].

  89. Kerr DJ, Ledermann JA, McArdle CS, et al. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol. Dec 1995;13(12):2968-72. [Medline].

  90. King MD, Young DG, Hann IM, Patrick WJ. Carcinoid syndrome: an unusual cause of diarrhoea. Arch Dis Child. Mar 1985;60(3):269-71. [Medline].

  91. Krishnamurthy SC, Dutta V, Pai SA, et al. Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. J Surg Oncol. Jul 1996;62(3):218-21. [Medline].

  92. Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol. May 2001;158(5):1803-8. [Medline]. [Full Text].

  93. La Ferla G, Baxter RA, Tavadia HB, Harper DR. Multiple colonic carcinoid tumours in a child. Br J Surg. Nov 1984;71(11):843. [Medline].

  94. Leake J, Levitt G, Ramani P. Primary carcinoid of the testis in a 10-year-old boy. Histopathology. Oct 1991;19(4):373-5. [Medline].

  95. Lee GH, Dietrich RB, Pais MJ, Wang NS. Pediatric case of the day. Neuroendocrine carcinoma (atypical carcinoid/Kulchitzky-cell carcinoma II). Radiographics. Jan 1994;14(1):188-91. [Medline].

  96. Lin KL, Chen CY, Hsu HH, et al. Ectopic ACTH syndrome due to thymic carcinoid tumor in a girl. J Pediatr Endocrinol Metab. Jul-Aug 1999;12(4):573-8. [Medline].

  97. Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg. 1995;28:317-36. [Medline].

  98. Loh KC, Yap WM, Chia FK. Ectopic Cushing's syndrome in a young female with atypical [corrected] bronchial carcinoid tumour. Singapore Med J. Jan 1997;38(1):29-31. [Medline].

  99. McDougall JC, Gorenstein A, Unni K, O'Connell EJ. Carcinoid and mucoepidermoid carcinoma of bronchus in children. Ann Otol Rhinol Laryngol. Sep-Oct 1980;89(5 Pt 1):425-7. [Medline].

  100. Mehta AC, Rafanan AL, Bulkley R, et al. Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. Chest. Feb 1999;115(2):598-600. [Medline]. [Full Text].

  101. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer. Feb 1968;21(2):270-8. [Medline].

  102. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. Feb 15 1994;120(4):302-9. [Medline]. [Full Text].

  103. Oliveira AM, Tazelaar HD, Wentzlaff KA, et al. Familial pulmonary carcinoid tumors. Cancer. Jun 1 2001;91(11):2104-9. [Medline].

  104. Parkes SE, Muir KR, al Sheyyab M, et al. Carcinoid tumours of the appendix in children 1957-1986: incidence, treatment and outcome. Br J Surg. Apr 1993;80(4):502-4. [Medline].

  105. Petzmann S, Ullmann R, Klemen H, et al. Loss of heterozygosity on chromosome arm 11q in lung carcinoids. Hum Pathol. Mar 2001;32(3):333-8. [Medline].

  106. Roberts WC, Sjoerdsma A. The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med. Jan 1964;36:5-34. [Medline].

  107. Rutledge RH, Alexander JW. Primary appendiceal malignancies: rare but important. Surgery. Mar 1992;111(3):244-50. [Medline].

  108. Ryden SE, Drake RM, Franciosi RA. Carcinoid tumors of the appendix in children. Cancer. Oct 1975;36(4):1538-42. [Medline].

  109. Sabback MS, O'Brien PH. Clinical study of 81 gastrointestinal carcinoid tumors. South Med J. Apr 1979;72(4):386-90. [Medline].

  110. Scully RE, Mark EJ, McNeely WF. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 9-1997. A 39-year-old woman with pernicious anemia and a gastric mass. N Engl J Med. Mar 20 1997;336(12):861-7. [Medline].

  111. Slodkowska J, Sikora J, Androsiuk W, et al. Lung carcinoids. Tumor angiogenesis in relation to clinicopathologic characteristics. Anal Quant Cytol Histol. Jun 1999;21(3):267-72. [Medline].

  112. Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer. Oct 1971;28(4):990-8. [Medline].

  113. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery. Jan 1992;111(1):48-54. [Medline].

  114. Teh BT, Hayward NK, Walters MK, et al. Genetic studies of thymic carcinoids in multiple endocrine neoplasia type 1. J Med Genet. Mar 1994;31(3):261-2. [Medline].

  115. Wada K, Asoh T, Imamura T, et al. Rectal carcinoid tumor associated with the Peutz-Jeghers syndrome. J Gastroenterol. Oct 1998;33(5):743-6. [Medline].

  116. Weissberg D. Video-assisted thoracoscopic pneumonectomy for bronchial carcinoid tumor in a 14-year-old girl. J Pediatr Surg. Jul 1997;32(7):1135. [Medline].

  117. Whelan T, Gatfield CT, Robertson S, et al. Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a child. J Urol. Mar 1995;153(3 Pt 2):1080-2. [Medline].

  118. Wilkin JK. Flushing reactions: consequences and mechanisms. Ann Intern Med. Oct 1981;95(4):468-76. [Medline].

  119. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet. Feb 2 1963;1:238-9. [Medline].

  120. Wong VG, Melmon KL. Ophthalmic manifestations of the carcinoid flush. N Engl J Med. Aug 24 1967;277(8):406-9. [Medline].

  121. Young RH, Kozakewich HP, Scully RE. Metastatic ovarian tumors in children: a report of 14 cases and review of the literature. Int J Gynecol Pathol. Jan 1993;12(1):8-19. [Medline].

 
Previous
Next
 
Distribution of carcinoid tumors.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.